18 February 2025
Annual Financial
Report
AstraZeneca PLC (the Company)
announced today the publication of its Annual Report and Form 20-F
Information 2024 (the Annual Report).
A copy of the Annual Report will be
submitted to the National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Annual Report is also available
on the Company's website www.astrazeneca.com.
The Annual Report will be dispatched
to shareholders in due course.
The Company's Annual General Meeting
(AGM) will take place on 11 April 2025. The Notice of AGM and
Shareholders' Circular will be published and distributed to
shareholders in due course.
EXPLANATORY NOTE
For the purposes of complying with
the Disclosure and Transparency Rules, the Annual Report being
submitted to the National Storage Mechanism contains the following
regulated information in unedited form:
-
the principal risks
and uncertainties facing the Company;
- the Directors' responsibility statement made in respect of the
Financial Statements and Directors' Report contained in the Annual
Report; and
-
a statement regarding related party
transactions.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
